ITAM2A: A Potential Drug Target and Biomarker for Various Diseases

Target Name: ITM2A

NCBI ID: G9452

ITM2A

ITAM2A: A Potential Drug Target and Biomarker for Various Diseases

The BRICHOS domain is a protein that plays a crucial role in the regulation of cell growth and differentiation. It is a multi-domain protein that is composed of four subdomains: BR, I, CHO, and OS. The BRICHOS domain is found in various cellular structures, including the nuclear envelope, endoplasmic reticulum, and cytosol. It is a protein that is involved in various cellular processes, including the regulation of cell adhesion, migration, and the transport of vesicles and organelles.

The ITM2A gene is a non-coding RNA molecule that is located in the BRICHOS domain. It is a member of the ITAM family, which includes proteins that are involved in the regulation of microRNA (miRNA) expression. ITAM2A is a 22-kDa protein that contains a unique N-terminal region that is composed of a long, single-stranded RNA molecule and a protein that is able to interact with the RNA.

The ITM2A gene has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. It is thought that ITM2A may be involved in the regulation of cellular processes that are important for the development and progression of these diseases.

The BRICHOS domain is a protein that is involved in the regulation of various cellular processes. It is a structural protein that is involved in the regulation of cell adhesion, migration, and the transport of vesicles and organelles. The BRICHOS domain is composed of four subdomains: BR, I, CHO, and OS. The BR subdomain is involved in the regulation of microRNA (miRNA) expression and has been shown to play a role in the regulation of various cellular processes.

The ITAM2A gene is a non-coding RNA molecule that is located in the BRICHOS domain. It is a member of the ITAM family, which includes proteins that are involved in the regulation of miRNA expression. ITAM2A is a 22-kDa protein that contains a unique N-terminal region that is composed of a long, single-stranded RNA molecule and a protein that is able to interact with the RNA.

The ITM2A gene has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. It is thought that ITM2A may be involved in the regulation of cellular processes that are important for the development and progression of these diseases.

Recent studies have shown that ITAM2A is involved in the regulation of various cellular processes, including the regulation of cell adhesion, migration, and the transport of vesicles and organelles. It is also involved in the regulation of microRNA (miRNA) expression and has been shown to play a role in the regulation of various cellular processes.

In conclusion, the BRICHOS domain is a protein that is involved in various cellular processes and has been shown to play a role in the regulation of miRNA expression. The ITAM2A gene is a non-coding RNA molecule that is located in the BRICHOS domain and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of ITAM2A in cellular processes and its potential as a drug target.

Protein Name: Integral Membrane Protein 2A

The "ITM2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITM2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets